Skip to main content
. 2021 Jun 29;11:703893. doi: 10.3389/fonc.2021.703893

Figure 4.

Figure 4

Progression-free and overall survival by occurrence of irAEs in a 14-week landmark analysis. (A) The median PFS under immunotherapy was 10 months (8.7–11.4) for patients without irAE vs. 17 months (10.3–23.6, logrank p = 0.003) for patients with irAEs in a 14-week landmark analysis. (B) The median OS was 15 months (13.5–16.6) for patients without irAE vs. 37 months (28.7–44.6, logrank p < 0.001) for patients with irAE in a 14-week landmark analysis.